Membrane-anchored CD40 is processed by the tumor necrosis factor-α-converting enzyme -: Implications for CD40 signaling

被引:114
|
作者
Contin, C
Pitard, V
Itai, T
Nagata, S
Moreau, JF
Déchanet-Merville, J
机构
[1] Univ Bordeaux 2, CNRS, UMR 5540, IFR 66, F-33076 Bordeaux, France
[2] Osaka Univ, Sch Med, Dept Genet, Osaka 5650871, Japan
关键词
D O I
10.1074/jbc.M209993200
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
The soluble form of CD40 (sCD40), which co-exists with the membrane-anchored form (mCD40), is a natural antagonist of mCD40/CD154 interaction. However, the mechanism leading to the production of sCD40 has never been investigated. Here, we show that the engagement of mCD40 on the surface of B lymphocytes by anti-CD40 antibody led to enhanced sCD40 release associated with decreased amounts of mCD40. This sCD40 production was not affected by vesicular traffic inhibitors but was completely blocked by a broad-spectrum synthetic metalloproteinase ( MP) inhibitor (GM6001) or a membrane-anchored MP-specific inhibitor (dec-RVKR-cmk). Recombinant MP disintegrin tumor necrosis factor-alpha converting enzyme ( TACE) cleaved the purified CD40 ectodomain/Fc chimeric protein in vitro, giving rise to an sCD40 form similar to that shed from B cell cultures. Moreover, spontaneous production of sCD40 by mCD40-transfected human embryonic kidney cells ( constitutively expressing TACE) was enhanced by the overexpression of TACE and abrogated by co-transfection with a dominant-negative TACE mutant. These results provide strong evidence that sCD40 production is an active process regulated by the engagement of mCD40 and its proteolytic cleavage by TACE or a related MP disintegrin. Given the antagonistic activity of sCD40 on the CD40/CD154 interaction, this shedding mechanism might represent an important negative feedback control of CD40 functions.
引用
收藏
页码:32801 / 32809
页数:9
相关论文
共 50 条
  • [1] Recent advances in tumor necrosis factor and CD40 signaling
    Tewari, M
    Dixit, VM
    CURRENT OPINION IN GENETICS & DEVELOPMENT, 1996, 6 (01) : 39 - 44
  • [2] Recruitment of CD40 and tumor necrosis factor receptor-associated factors 2 and 3 to membrane microdomains during CD40 signaling
    Hostager, BS
    Catlett, IM
    Bishop, GA
    JOURNAL OF BIOLOGICAL CHEMISTRY, 2000, 275 (20) : 15392 - 15398
  • [3] CD40 signaling and CD40/TLR cross-talk in inflammation
    Suttles, J.
    Head, K. Z.
    Jiang, C.
    Zhang, L.
    Stout, R. D.
    SHOCK, 2006, 25 : 3 - 3
  • [4] Ligation of CD46 to CD40 inhibits CD40 signaling in B cells
    Jabara, Haifa H.
    Angelini, Federica
    Brodeur, Scott R.
    Geha, Raif S.
    INTERNATIONAL IMMUNOLOGY, 2011, 23 (03) : 215 - 221
  • [5] SPECIFIC ROLE OF CD40/CD40 L SIGNALING DURING ALLOGRAFT REJECTION
    Granofszky, N.
    Mahr, B.
    Pilat, N.
    Unger, L.
    Wekerle, T.
    TRANSPLANT INTERNATIONAL, 2017, 30 : 16 - 16
  • [6] Regulation of CD40 and CD40 ligand by the AT-hook transcription factor AKNA
    Aisha Siddiqa
    Jennifer C. Sims-Mourtada
    Liliana Guzman-Rojas
    Roberto Rangel
    Christiane Guret
    Vicente Madrid-Marina
    Yan Sun
    Hector Martinez-Valdez
    Nature, 2001, 410 : 383 - 387
  • [7] Regulation of CD40 and CD40 ligand by the AT-hook transcription factor AKNA
    Siddiqa, A
    Sims-Mourtada, JC
    Guzman-Rojas, L
    Rangel, R
    Guret, C
    Madrid-Marina, V
    Sun, Y
    Martinez-Valdez, H
    NATURE, 2001, 410 (6826) : 383 - 387
  • [8] CD40 signaling and plaque instability
    Schönbeck, U
    Libby, P
    CIRCULATION RESEARCH, 2001, 89 (12) : 1092 - 1103
  • [9] Induction of an Altered CD40 Signaling Complex by an Antagonistic Human Monoclonal Antibody to CD40
    Bankert, Katherine C.
    Oxley, Kyp L.
    Smith, Sonja M.
    Graham, John P.
    de Boer, Mark
    Thewissen, Marielle
    Simons, Peter J.
    Bishop, Gail A.
    JOURNAL OF IMMUNOLOGY, 2015, 194 (09): : 4319 - 4327
  • [10] Molecular mechanisms of CD40 signaling
    Bishop, GA
    Hostager, BS
    ARCHIVUM IMMUNOLOGIAE ET THERAPIAE EXPERIMENTALIS, 2001, 49 (02) : 129 - 137